Public policy and patient advocacy
Through our lobbying and public policy activity we monitor proposed legislative reforms, policy developments and concerns from government officials, NGOs and other organisations. We aim to support programmes that encourage scientific innovation and balance the interests of business with those of others. We also work with patient and professional groups to help their members gain a stronger voice on healthcare.
We aim to demonstrate that all our interactions with political stakeholders and patient advocacy groups are conducted appropriately, ethically and transparently. We publish our criteria for working with public policy groups to give clarity on our approach.
Medicines and vaccines bring significant benefits for individual patients and for public health. In order to realise these benefits we need to interact with external groups throughout the research, development and marketing of our medicines and vaccines. This enables us to use the expertise of patients, scientists, doctors and other healthcare professionals to better understand how to conduct the most effective research, how to make treatment advances and how to meet patient needs.
In some instances these interactions involve GSK providing funding to an organisation or an individual. We know these relationships can cause concern and we therefore aim to be transparent about the payments we make and what they are for.
Patient group funding
We provide funding to patient groups to help with day-to-day running costs and defined events or activities. Our support also includes educational assistance, training for staff, and collaboration on disease awareness and prevention projects. Our relationships with patient groups help us to better understand patient needs and their illnesses, which guides our R&D. In turn, our support helps patient opinions to be heard in the healthcare debate.